Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AGIO | PRESS-RELEASE | mixed | 7/10 | Agios presented detailed Phase 3 RISE UP data for mitapivat in sickle cell disease at EHA 2026, showing statistically si | Jun 13, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide in Prader-Willi syndrome at ENDO 2026, showing c | Jun 13, 2026 |
| NTLA | PRESS-RELEASE | bullish | 8/10 | Intellia presented additional positive Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE at EAACI 2026, with the manuscr | Jun 13, 2026 |
| RKDA | PRESS-RELEASE | bearish | 7/10 | Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds through the sale of co | Jun 12, 2026 |
| LYEL | PRESS-RELEASE | neutral | 4/10 | Lyell Immunopharma presented updated Phase 1/2 safety and translational data for its CAR T-cell therapy ronde-cel at EHA | Jun 12, 2026 |
| GELS | PRESS-RELEASE | neutral | 4/10 | Gelteq announced successful veterinary palatability trials with Kemin Industries, validating its gel-based drug delivery | Jun 12, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber terminated its ATM facility with Maxim Group, citing a strengthened balance sheet after receiving over $15 | Jun 12, 2026 |
| LIXT | PRESS-RELEASE | bullish | 7/10 | LIXTE Biotechnology (LIXT) announced a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, a lead | Jun 12, 2026 |
| IRON | PRESS-RELEASE | bullish | 8/10 | Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusio | Jun 12, 2026 |
| COGT | PRESS-RELEASE | bullish | 7/10 | Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvS | Jun 12, 2026 |
| COGT | PRESS-RELEASE | neutral | 4/10 | Cogent Biosciences presented preclinical data for its novel JAK2 V617F mutant-selective inhibitor CGT1145 at the EHA Con | Jun 12, 2026 |
| SCLX | PRESS-RELEASE | neutral | 2/10 | Scilex Holding Company confirmed the payment date of June 15, 2026 for its previously announced dividend of Semnur Pharm | Jun 12, 2026 |
| BCRX | PRESS-RELEASE | neutral | 4/10 | BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained H | Jun 12, 2026 |
| KYMR | PRESS-RELEASE | neutral | 3/10 | Kymera presented Phase 1 data for KT-621 (oral STAT6 degrader) in healthy Japanese adults at the JDA Annual Meeting, sho | Jun 12, 2026 |
| MBX | PRESS-RELEASE | bullish | 6/10 | MBX Biosciences announced full Phase 2 and one-year open-label extension data for canvuparatide in hypoparathyroidism, s | Jun 12, 2026 |
| AUTL | PRESS-RELEASE | neutral | 3/10 | Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product, a prestigious industry recog | Jun 12, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion receives the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform. While th | Jun 12, 2026 |
| RKDA | PRESS-RELEASE | bearish | 7/10 | Arcadia Biosciences announces a private placement of ~3.88M common shares (or pre-funded warrants) plus two series of pr | Jun 11, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs | Jun 11, 2026 |
| ADIL | PRESS-RELEASE | bullish | 7/10 | Adial Pharmaceuticals acquires Azora Therapeutics and secures up to $64M in private placement, pivoting to a colon-targe | Jun 11, 2026 |
| CRBU | PRESS-RELEASE | bullish | 7/10 | Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-t | Jun 11, 2026 |
| TOVX | PRESS-RELEASE | bullish | 7/10 | Theriva Biologics announced publication of Phase 1 trial results for VCN-01 in immunotherapy-refractory HNSCC in Clinica | Jun 11, 2026 |
| SNDX | PRESS-RELEASE | bullish | 7/10 | Syndax presented 12 abstracts on revumenib at EHA 2026, including real-world data showing 82% ORR in R/R NPM1m/KMT2Ar pa | Jun 11, 2026 |
| CCCC | PRESS-RELEASE | bullish | 6/10 | C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA 2026, showing a 53% overall response rate at the 1 | Jun 11, 2026 |
| OCS | PRESS-RELEASE | neutral | 3/10 | Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privosegtor, a peptoid small | Jun 11, 2026 |
| CLLS | PRESS-RELEASE | bullish | 7/10 | Cellectis presented final Phase 1 data for lasme-cel (CD22 allogeneic CAR-T) in r/r B-ALL at EHA 2026, showing 100% ORR | Jun 11, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in hu | Jun 11, 2026 |
| HUMA | PRESS-RELEASE | bearish | 6/10 | Humacyte priced a $50M underwritten public offering of 47.6M shares at $1.05 per share, representing a roughly 20% disco | Jun 10, 2026 |
| HUMA | PRESS-RELEASE | bearish | 5/10 | Humacyte, Inc. has commenced an underwritten public offering of its common stock. The size and pricing of the offering h | Jun 10, 2026 |
| HUMA | PRESS-RELEASE | bullish | 7/10 | Humacyte announced positive top-line interim results from the V012 Phase 3 study of its acellular tissue engineered vess | Jun 10, 2026 |